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Abstract
One of the challenges in the design of confirmatory trials is to deal with uncertainties
regarding the optimal target population for a novel drug. Adaptive enrichment designs
(AED) which allow for a data-driven selection of one or more pre-specified biomarker
subpopulations at an interim analysis have been proposed in this setting but practical
case studies of AEDs are still relatively rare. We present the design of an AED with
a binary endpoint in the highly dynamic setting of cancer immunotherapy. The trial
was initiated as a conventional trial in early triple-negative breast cancer but amended
to an AED based on emerging data external to the trial suggesting that PD-L1 status
could be a predictive biomarker. Operating characteristics are discussed including the
concept of a minimal detectable difference, that is, the smallest observed treatment
effect that would lead to a statistically significant result in at least one of the target
populations at the interim or the final analysis, respectively, in the setting of AED.
1 Introduction
Cancer immunotherapy (CIT) has revolutionized the treatment of cancer patients. CIT is
able to stimulate and promote the immune system and to engage it in the fight against
cancer. The immune system normally recognizes and eliminates most early tumor cells, but
immunological checkpoints (e.g. PD-L1) constitute a significant obstacle to effective antitumor
immune responses1. An important class of CITs are PD1 and PD-L1 inhibitors1. PD-L1
protein expression on tumor or immune cells has emerged as a potential predictive biomarker
for sensitivity to such CITs. However, uncertainty remains on the value of PD-L1 as a
predictive biomarker which may vary by cancer type or stage2, as immune-based interactions
are dynamic and complex in nature.
A major topic in research and development of CITs is thus the identification and confirmation
of subgroups of patients where a treatment is (most) effective3 and dealing with uncertainties
regarding the optimal target population is an important consideration in the design of pivotal
CIT trials. If there is confidence at the time of the design of the pivotal trial that the
biomarker has the ability to identify patients who will benefit from the treatment, then
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the trial can be limited to the biomarker-positive patients (that is, the trial is enriched at
the beginning). If the biomarker is appropriately developed but confidence in its ability to
fully identify the correct biomarker population is lacking, then a separate Phase II study
investigating the biomarker population could be conducted to inform the Phase III trial design.
Alternatively, a single confirmatory adaptive enrichment design (AED) could be conducted
which allows a data-driven selection of one or more pre-specified biomarker subpopulations
at an interim analysis, and the confirmatory proof of efficacy in the selected subset at the
end of the trial4,5.
Regulatory guidance documents for confirmatory adaptive designs are available and stress
the importance of prospective planning of adaptations and strong type I error control6,7.
Moreover, an ICH guideline8 on adaptive trials is in preparation. However, although the
methodological foundation for adaptive designs was established more than 30 years ago, their
impact in drug development has not been as high as anticipated9. In particular, practical case
studies of AEDs are still rare. For example, according to a recent review of 59 medicines for
which an adaptive clinical trial had been submitted to the EMA Scientific Advice, only 5/59
(8%) concerned AED and for only one of them, it could be established that the corresponding
trial was actually initiated10.
In this article, we present a case study of a confirmatory AED in CIT. This trial compares a
CIT (atezolizumab) plus chemotherapy versus chemotherapy alone in early triple-negative
breast cancer (TNBC) with pathological complete response as the primary (binary) endpoint.
The trial was originally planned as a conventional randomized trial in all-comers but then
converted to an AED based on emerging data external to the trial suggesting that PD-
L1 could be a predictive biomarker for the atezolizumab treatment effect in TNBC. The
remainder of this article is structured as follows. Section 2 outlines the general methodological
framework for an AED with a binary clinical endpoint. This section also contains a discussion
of the minimal detectable difference (MDD), an important concept for the design of a trial.
In Section 3, the methodology is applied to our case study. The article concludes with a
discussion.
2 Adaptive enrichment designs with binary endpoints
2.1 General description
At the design stage of a trial, it is often uncertain whether all patients or only a targeted
subgroup will benefit from the experimental treatment. Adaptive enrichment designs (AED)
which allow for a data-driven population selection at interim analyses have been proposed in
this setting4,11. The general methodology to control for multiple testing in such designs via
p-value combination tests and the closed testing principle was described in Brannath et al12.
In this section, we summarize the theory of AEDs with a focus on methods relevant to our
case study which is a two-stage AED with two sub-populations defined by a dichotomized
biomarker and a binary endpoint (responder vs non-responder). We refer to Section 11.2 of
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Wassmer and Brannath13 for a detailed discussion of the general case with multiple stages
and sub-populations and general endpoints and to14 for a systematic review of methods for
identification and confirmation of targeted subgroups in clinical trials. In the last part of
this section, we discuss the calculation of the minimum detectable difference (MDD), which
translates the local significance levels to the clinically more interpretable treatment effect
scale. To our knowledge the MDD has not been discussed in the AED setting previously.
Let F denote the full population, S the sub-population of subjects tested positive for a binary
biomarker of interest, and C the subgroup of biomarker-negative subjects. The true response
probability in the experimental arm in S and F is denoted by piq1 with q ∈ {F, S} and the
corresponding probability in the control arm is piq2. The two one-sided null-hypotheses of
interest are H0,q : piq1 − piq2 ≤ 0 versus the alternatives HA,q : piq1 − piq2 > 0 for q ∈ {F, S}.
A flow chart of a pivotal AED in this setting is shown in Figure 1. In stage 1 of the trial, n1
patients from the full population are randomized to the experimental treatment or control
and F and S are co-primary populations. After data from stage 1 is available, a pre-specified
interim analysis is conducted and one of the following decisions is taken based on decision
criteria as discussed in Section 2.3:
1. Stop early for efficacy in F or S or both.
2. Stop early for futility in both F and S.
3. Continue to stage 2 with S as the target population, that is, randomize an additional
n2 patients from S in stage 2, and only test H0,S at the final analysis.
4. Continue to stage 2 with F as the target population, that is, randomize an additional
n2 patients from F in stage 2, and only test H0,F at the final analysis.
5. Continue to stage 2 with F and S as co-primary populations, that is, randomize an
additional n2 patients from F in stage 2, and test both H0,S and H0,F at the final
analysis.
Figure 1: Flow chart of adaptive enrichment design as defined above
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Decision 1 provides an early opportunity to declare efficacy in case an overwhelming benefit is
observed in F or S (or both). Decision 2 avoids exposing additional patients to a potentially
inefficacious experimental treatment. The other three decisions are applicable if a promising
signal is seen but it is not pronounced enough for an early read-out.
Decision 3 is chosen when the biomarker is strongly predictive of treatment benefit, hence
maximizing the power to reject HS0 as well as avoiding to expose patients in C to an
ineffective treatment with some potential safety reactions. Decisions 4 and 5 are appropriate
if a promising signal is observed in both S and C (or F ). Dropping S as a target population
in Decision 4 is sensible when e.g. the predictive value of the relevant biomarker is weak,
hence dropping HS0 and maximizing the probability to reject HF0 .
2.2 Type I error control
In an AED, type I error can be controlled by combining closed testing15 with adaptive p-value
combination. Denote the unadjusted stage-wise one-sided p-values (testing for superiority of
the intervention arm) corresponding to the null hypotheses Hq0 (q ∈ {F, S}) based on data
from stage i (i ∈ {1, 2}) by pqi .
Multiplicity in target populations is circumvented by using a closed testing procedure. For
two target populations, the closed testing principle implies that significance in S or F can
only be declared if the test of the intersection null hypothesis HS0 ∩HF0 can also be rejected.
Several choices for the test of the intersection hypothesis are possible, see Section 11.2 of
Wassmer and Brannath13. We use the Simes test16 because it protects type I error without
requiring strong assumptions and is more powerful than the Bonferroni test.
The design of the second stage of a two-stage AED, especially selection of the target popula-
tion(s) and associated test hypothesis(es), is driven by trial data from the first stage which
prohibits “naive” analyses via pooling data across stages. To remedy this, stage-wise p-values
can be combined by using inverse normal combination tests17. Define Z-values corresponding
to stage 1 p-values by Z1 = Φ−1 (1− p1) for p1 ∈ {pF1 , pS1 , p(F,S)1 } and corresponding values
Z2 for stage 2 accordingly. A combined Z-value accross both stages is then defined as
Z˜2 = w1Z1 +w2Z2 with non-negative weights w1 and w2 satisfying w21 +w22 = 1. The p-value
corresponding to Z˜2, that is, p˜2 = 1− Φ(Z˜2), is referred to as the combined p-value.
The weights have to be pre-specified at the design stage. In our case study, we use the common
definition of the weights according to the pre-planned stage-wise sample sizes n1 and n2:
w21 = n1/(n1 + n2) and w22 = n2/(n1 + n2). These weights are optimal if the actual stage-wise
sample sizes are proportional to the planned stage-wise sample sizes in each population.
Note that discrepancies from this proportionality are expected in case the trial is enriched
at stage 2 and only subjects from S are recruited. However, it has been shown that the
associated power loss from this is rather limited in all but extreme cases which is unlikely to
our setting17.
Regardless of the adaptations after stage 1, Z1 and Z˜2 follow the same bivariate distribution
as a standard group sequential test with two interim analyses at information fractions t1 = w21
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and t2 = 1. Thus, standard statistical software for group sequential designs can be used for
the determination of local significance levels α1 and α2 after each stage which allow for early
stopping for efficacy and protect the ovarall significance levels across both Z-tests.
Following the aforementioned close-test principle and combined p-value combination approach,
overall test decisions which control the family-wise type I error in the strong sense are then
defined as follows:
• HF0 is rejected after stage 1 if p
(F,S)
1 ≤ α1 and pF1 ≤ α1.
• HS0 is rejected after stage 1 if p
(F,S)
1 ≤ α1 and pS1 ≤ α1.
• HF0 is rejected after stage 2 if F is a target population in stage 2, with p˜
(F,S)
2 ≤ α2 and
p˜F2 ≤ α2.
• HS0 is rejected after stage 2 if if S is a target population in stage 2, with p˜
(F,S)
2 ≤ α2
and p˜S2 ≤ α2.
Stopping for futility is discussed in Section 2.3.
2.3 Decision criteria, determination of sample size and other de-
sign parameters
If the AED cannot be stopped for compelling efficacy after stage 1, a decision must be made
whether to stop for futility or to continue to stage 2 with one or both populations. Decision
criteria may be based on the observed treatment effect in S and C (and/or F ) after stage
1 (e.g.11 and our case study), conditional or predictive power (e.g.18), or Bayesian decision
theory (e.g.19–21). While type I error control is guaranteed regardless of how these choices
are made, the decision criteria affect the probability of correct decisions after stage 1 and
study power.
In general, the design parameters for an AED include (1) the sample sizes n1 and n2 of
stage 1 and 2, rescectively, where n2 could be re-calculated at the interim analysis, (2) the
α-spending approach for early stopping for efficacy, (3) the exact decision criteria (thresholds)
used for population selection criteria as well as for early stopping for futility.
In practice, these design parameters are usually determined by running simulations across a
range of plausible scenarios and evaluating design characteristics such as: the overall power
of the study, that is, the probability of a statistically significant result for either of the target
populations or both at either the interim or final analysis, the conditional power, that is, the
probability of a significant result conditional on continuing to stage 2, and the probability of
making the “correct” decision(s) at the interim analysis. Overall power measures the success
probability of the entire AED whereas conditional power assesses the probability of success of
the additional investment into stage 2. Usually, a trade-off between overall and conditional
power needs to be made because maximizing the latter leads to aggressive thresholds for
futility stopping and population selection which may reduce overall power.
Of note, often “biomarker status” could be used as stratification factor for randomization
and analysis. We adopt a common practice, which is to neglect this in sample size calculation
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for the case study in this paper.
2.4 Minimal detectable difference
In Section 2.2, it was outlined how to determine local significance levels α1 and α2, that
is, boundary values based on which test decisions can be taken as described at the end of
Section 2.2.
To support clinical interpretation of these local significance levels, it is useful to express them
on the treatment effect scale. We denote this as the minimal detectable difference (MDD),
that is, the smallest observed absolute risk difference between the two groups which would
lead to rejection of the corresponding null hypothesis after stage 1 or 2, respectively.
MDDs (also called boundary values on the treatment effect scale) are routinely provided for
single stage or group-sequential trials by standard software such as rpact22 (version 2.0.5)
and an extension to AEDs is described below.
We first consider a single stage trial and a statistical test of the null hypothesis H0 : ∆ =
pi1− pi2 ≤ 0 versus the alternative HA : ∆ = pi1− pi2 > 0 at the one-sided significance level α∗.
The observed proportion of pˆi2 in the control arm serves as a nuisance parameter in this setting
and, typically, it is assumed to correspond to the hypothesized control proportion from the
sample size calculation. Given pˆi2, the MDD δ∗ corresponds to the observed difference between
the two arms which would lead to a p-value of exactly α∗ using e.g. a signed (one-sided)
chi-squared test for hypothesis testing. Numerically, the MDD can be calculated with any
one dimensional root (zero) finding algorithm. If there is substantial uncertainty regarding
the true response probability in the control arm, the MDD should be calculated for a range
of plausible values.
In an AED, MDDs which lead to the rejection of the respective population null hypothesis
after stage 1 can be calculated in the same way as for a single stage trial. The only additional
complication is that the corresponding null hypothesis for each population can only be rejected
if the intersection hypothesis is also rejected. If Simes test is used to test the intersection
hypothesis, the intersection hypothesis and the null hypothesis for S can both be rejected after
stage 1 if either 2pS1 ≤ α1 (that is, S alone is responsible for the rejection of the intersection
null hypothesis) or if both pS1 ≤ α1 and pF2 ≤ α1 (that is, F contributes to the rejection of
the intersection null hypothesis). Consequently, two MDDs can be calculated for S: First,
a conservative MDD for S which assumes that S alone is responsible for rejection of the
intersection null hypothesis and corresponds to the MDD for a single stage trial based on the
“adjusted” p-value 2pS1 . Second, a more liberal MDD which is only applicable if F contributes
to the rejection of the intersection null hypothesis (and hence is also significant with a smaller
p-value than S), and corresponds to the MDD for a single stage trial based on the raw p-value
pS1 . Both, the conservative and liberal MDD will be useful in design discussions with the
drug development team. In an analogous way, two MDDs can be calculated for F .
MDD calculations after stage 2 are based on the combination test and require additional
consistency assumptions to achieve a unique solution. First, we assume that the estimated
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proportions in each arms are identical for stage 1 and stage 2 data, respectively.
If only S continues to stage 2, the intersection test is only relevant for the stage 1 data and
it is plausible to additionally assume consistency in the driver for the treatment effect, that
is, that the stage 1 p-value for Simes test is driven by S alone and given by 2pS1 . Thus, the
MDD for S after stage 2 corresponds to the observed difference between the two arms which
would lead to a p-value of exactly α2 using the combination test based on the adjusted stage
1 p-value 2pS1 and the raw stage 2 p-value pS2 . If only F continues to stage 2, the MDD can
be calculated in an analogous way.
If both S and F continue to stage 2, we propose to calculate a conservative MDD for S using
an adjusted stage 1 p-value 2pS1 and an adjusted stage 2 p-value 2pS2 for the combination test
(assuming that the intersection test is driven by S alone in both stages) and a more liberal
MDD for S based on the raw stage 1 p-value pS1 and the raw stage 2 p-value pS2 (which is
only valid if F contributes to the rejection of the intersection test in both stages). In the
same way, a conservative and a liberal MDD can be calculated for F .
As described above, MDDs can only be derived under additional assumptions. While these
assumptions will often be approximately true, it is important to recognize that formal
test decisions should be based on the local significance levels α1 and α2 and not on the
MDD. However, the MDD is on a clinically relevant scale, and as such extremely helpful
for a discussion of the trial design with the cross-functional clinical development teams. For
example, if the MDD is very small, this indicates that it is possible that the observed treatment
effect is not clinically relevant but that the trial is nevertheless statistically significant. This
would make it very difficult to market the drug and hence, such a finding may lead to a
re-consideration of the trial sample size.
3 Application: the IMpassion031 trial
3.1 The original IMpassion031 trial design
IMpassion031 is a global Phase III, double-blind, 1:1 randomized, multicenter, placebo-
controlled study which is conducted to evaluate the efficacy and safety of neoadjuvant
treatment with nab-paclitaxel + doxorubicin + cyclophosphamide and either atezolizumab
or placebo in invasive stage II/III early triple-negative breast cancer (TNBC). The CIT
atezolizumab is an anti-programmed death-ligand 1 (PD-L1) monoclonal antibody that blocks
the binding of PD-L1 to PD-1 and B7.1 receptors, thereby restoring tumor-specific immunity.
The primary efficacy endpoint of IMpassion031 is pathological complete response (pCR), a
binary clinical endpoint evaluated at surgery which takes place approximately 6 months after
randomization for patients in both arms. pCR in this study is defined as absence of residual
invasive cancer in the complete resected breast specimen and all sampled regional lymph
nodes following completion of neoadjuvant therapy23. The original IMpassion031 trial had a
fixed non-adaptive design with a one-sided significance level of 2.5% and a target sample size
of 204 subjects from the overall population F , randomized 1:1 to receive either atezolizumab
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in combination with chemotherapy or chemotherapy alone. This yields a power of 79% to
detect an increase of 20% pCR rate in the combo arm from a true pCR rate of 48% in the
mono arm, accounting for 5% drop-out rate in both treatment arms, whereby drop-outs are
considered non-responders. Chi-square test for two proportions was considered.
The trial was initiated on 24th July 2017 and recruitment of the original 204 subjects
independent of PD-L1 status was completed on 12th June 2018, with 205 patients actually
enrolled. During patient follow-up and prior to study unblinding, data external to the trial
emerged suggesting that PD-L1 could be a predictive biomarker for the treatment effect of
atezolizumab in metastatic or locally advanced TNBC (IMpassion13024). Although results of
IMpassion130 were compelling with respect to the predictive nature of PD-L1 biomarker, the
extent to which this finding would apply to the early TNBC setting was uncertain. Therefore,
the original fixed design was changed to an AED to address this potential predictive biomarker
population hypothesis. PD-L1 status was dichotomized according to a pre-specified cut-point
which has been previously used and validated in the pivotal trial in advanced TNBC25.
3.2 The IMpassion031 AED
By the time of the protocol amendment, that is, when transforming the trial to an AED, the
target sample size for the original design had already been fully enrolled and follow-up was
ongoing. Thus, this phase of the trial was assigned as stage 1 of the new AED with n1 = 205
subjects.
The new AED design has the following features. The overall one-sided type-I error level is
α = 2.5% and both used a 1:1 randomization ratio. After the interim analysis at the end of
stage 1, to safeguard the scientific integrity of the study, an independent data monitoring
committee will look at unblinded data to make recommendations to the trial sponsor regarding
early stopping for efficacy or futility or continuing into stage 2 with the target population(s)
selected, following the general framework laid down in Section 2 and displayed in Figure 1.
The sample size of n2 = 120 subjects for stage 2 is determined based on its favorable design
characteristics such as power (see below) without adding too much operational complication
such as extension of study duration. Importantly, the protocol amendment was completed and
submitted to regulatory authorities while the treatment assignment remained double-blinded,
hence protecting the integrity of the trial.
Type I error control is implemented by combining closed testing via Simes test with p-value
combination using inverse normal combination tests as described in Section 2. In order to
allow for an acceptably high probability that the trial stops after stage 1, that is, the sample
size of the original trial, 50% of the overall type I error is spent at stage 1 which implies local
significance levels of α1 = 0.0125 and α2 = 0.0184.
Adaptive sample size re-calculation after stage 1 is not considered since the design with fixed
stage 2 sample has sufficient power and allowed to control the overall trial timelines. The
selection of target population(s) for stage 2 and futility decisions are based on the observed
treatment effect, that is, the difference of pCR rates between the two arms, after stage 1
in the PD-L1 positive population S and its counterpart, the PD-L1 negative population C.
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Based on clinical trial simulations (reported below) and discussion with clinicians, futility
decision thresholds dS = 12% and dC = 10% are chosen. Thus, if the observed treatement
effect in the PD-L1 positive population is ≥ 12% after stage 1, it is included as a target
population in stage 2. Similarly, if the observed treatment effect in the PD-L1 negative
population is ≥ 10% after stage 1, the full population F is included as a target population in
stage 2. If both treatment effects exceed the threshold, both populations are included and
tested as co-primary populations at the final analysis. If neither treatment effect is above the
threshold, the trial stops for futility. Decisions concerning F are predicated on the observed
treatment in the PD-L1 negative population instead of the full population to avoid cases
where the benefit in F is strongly driven by S, hence minimizing the risk of exposing patients
in C to a potentially futile treatment independent of its activity in S.
Simulations are used to investigate the properties of the chosen AED and the decision
thresholds dS and dC . Three scenarios are reported here which all assume a prevalence of
47% of the PD-L1 positive subgroups (based on internal and external information such as
Kwa et. al26), a pCR rate of 48% in the control arm, and a treatment effect of 20% in the
PD-L1 positive subgroup. The treatment effect in PD-L1 negative subjects is varied between
4%, 12%, and 20% (Table 1). The original trial design assumed a homogenous treatment
effect of 20% in the full population but scenarios with a reduced treatment effect in PD-L1
negative patients are also plausible in view of the external information that triggered the
amendment to IMpassion031. Of note, all simulations assumed a drop-out rate of 5% in
both treatment arms and stages independent of the pCR outcome and that drop-outs were
considered non-responders. Therefore, as an example, an underlying control arm pCR of
0.48×0.95=0.456 is considered in our simulation”.
Results of the simulations are displayed in Tables 2-4. In addition to the chosen decision
thresholds of dS = 12% and dC = 10%, results for an alternative set of more aggressive
decision thresholds d′S = 15% and dC ’=12% are also displayed for comparison purposes.
Reported results for each scenario represent averages over 100,000 simulated trials.
Under the original trial assumptions (scenario 1), the overall probability to stop for efficacy
(that is, reject either H0,S or H0,F or both) after stage 1 is 64% compared to a power of 79%
for the original trial design (Table 2). This quantifies the price for the additional flexibility
of two co-primary populations, the choice of the target population for stage 2, and a second
opportunity to declare efficacy after stage 2. The futility decision thresholds dS and dC do
not impact the estimated probabilities of stopping for efficacy at stage 1. However, the more
aggressive (higher) decision thresholds almost double the likelihood for futility stopping in
all scenarios, whereas they reduce the likelihood of continuing to stage 2 with only patients
from S. Similarly, using the more aggressive thresholds reduce the chance of continuing to
stage 2 with both S and F whereas the chance of continuing only in F is slightly increased
in all scenarios. This latter finding is mainly due to the fact that many of the simulated
trials which would continue to stage 2 with both F and S for the less aggressive thresholds
continue with only F for the more aggressive thresholds due to the larger increase from dS to
d′S compared to the increase from dC to d′C . Hence, dS = 12% and dC = 10% are considered
the better choice due to the lower chance of stopping for futility as well as higher chance to
continue in either S or both F and S, which provides more confidence to clinicians based on
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the mode of action of our active treatment.
The overall power for the revised IMpassion031 design is 88% (versus 79% for the original
design) for scenario 1, 76% (versus 57%) for scenario 2, and 67% (versus 35%) for scenario 3
(Table 3). While the power is still below 80% for scenarios with a reduced treatment benefit
in PD-L1 negative patients, it is substantially increased compared to the original design. An
even larger increase in power would have required a larger stage 2 sample size, which would
have put challenges on recruitment feasibility and timelines, in particular if one would only
continue with S in stage 2.
More aggressive thresholds for assessing futility and population selection would lead to a
general drop in overall power (Table 3) but increase the conditional power, that is, the
conditional rejection probabilities if stage 2 is activated (Tables 4). However, one needs
to take into account the greater risk of not activating stage 2 with the more aggressive
thresholds.
Finally, MDDs for IMpassion 031 are displayed in Table 5. An observed difference in response
rates of at least 17% in F or at least 25% in S (or a difference of both at least 16% in F
and at least 22% in S jointly) is required for an efficacy stop after stage 1. After stage 2,
the smallest MDD is 12% for F which applies if F and S are both tested at stage 2 and
the treatment effect in S alone is also at least 17%. These MDDs were all considered to
correspond to clinically relevant effect sizes.
Of note, the futility boundaries at the interim were dS = 12% and dC = 10% (consistent
with a treatment effect of ≈ 11% in F ). These values are smaller than the calculated MDDs
after stage 2. If this were not the case, the same observed treatment effect might lead to a
futility stop at the interim analysis but also to a rejection of the null hypothesis at the final
analysis. This would be incoherent and should lead to a re-assessment of the planned futility
boundaries.
4 Discussion
The world of cancer immunotherapies (CITs) is highly dynamic and data external to an
ongoing trial is evolving quickly. In this paper, we showed that it is possible to incorporate
emerging data regarding the most appropriate target population into an ongoing trial by
amending it to an adaptive enrichment trial (AED). The implemented two-stage AED allows
for both efficacy and futility stopping after stage 1, as well as for population selection for stage
2. Importantly, the protocol was amended and submitted to regulatory agencies while stage
1 was still ongoing and prior to any unblinding of the double-blind trial, hence protecting the
integrity of the design.
This paper also introduced the concept of the minimal detectable difference (MDD) to AED,
which is relevant for the discussion of the design with stakeholders beyond biostatistics.
The proposed AED in CIT addresses several important considerations highlighted in the recent
adaptive trials guidance by the FDA for enrichment designs6: First, the design combines
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established statistical methods to protect the familywise type I error in the strong sense.
Second, the data external to the trial provided a strong rationale that the benefit-risk profile
may be more favorable in the PD-L1 positive subgroup. Third, the PD-L1 assay and the
threshold used to define PD-L1 positivity had been previously validated25. Fourth, stage 1 of
the trials was large enough to characterize the treatment effect in the complement population,
that is, the PD-L1 negative subgroup, even in the situation when only PD-L1 positive subjects
would be included in stage 2.
However, our proposal also has several limitations. The amendment was promptly imple-
mented following the release of the external data, but this occurred only after recruitment to
stage 1 of the trial had already been completed. This prevented optimization of some design
parameters of the AED such as the stage 1 sample size. Moreover, our derivation of the MDD
relied on the simple dependence of Simes’ test on the p-values from each population. If more
complex intersection tests are employed, e.g. the test proposed by Spiessen and Debois27,
this would further complicate the quantification of the dependence of test decisions for each
population on the intersection test. In addition, we focused on hypothesis testing but did not
cover estimation and inference in AEDs which is an important area of current research. We
refer to Chapter 8 of Wassmer and Brannath13 for a general discussion for adaptive trials
and to Kunzman et al28 for a discussion of estimation in the context of AEDs. Finally, the
current setting of a binary endpoint is methodologically easier than the time-to-event setting,
which is frequent in oncology, where additional complications arise11,29.
In summary, this case study demonstrated that AED are an efficient way to circumvent
emerging uncertainties about the target population for cancer immunotherapy. AEDs are
still relatively rarely used in clinical development and we hope that this paper promotes their
use and increases the confidence that such designs are feasible in practice.
5 Software
The code and the results of all computations described in this paper are available as a GitHub
repository: https://github.com/nguyenducanhvn101087/Enrichment_Adaptive_Design
6 Data Availability Statement
Data sharing is not applicable to this article as no new data were created or analyzed in this
study.
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7 Tables
Table 1: Scenarios investigated in the clinical trial simulations
Scenario piS1 − pi2 piC1 − pi2 piF1 − pi2 pi2
1 0.20 0.20 0.20 0.48
2 0.20 0.12 0.16 0.48
3 0.20 0.04 0.12 0.48
piq1 is the pCR rate in intervention arm for pop-
ulation q, q ∈ (F, S,C). pi2 is the pCR rate in
control arm assumed to be the same for S and C.
Numbers in the table refer to true pCR rates.
Table 2: Relative Frequencies of Decisions at Stage 1 for IMpassion031 for the different
scenarios and different futility decision thresholds
dS = 0.12, dC = 0.1 dS = 0.15, dC = 0.12
Decision Scen. 1 Scen. 2 Scen. 3 Scen. 1 Scen. 2 Scen. 3
1a - Stop after stage 1: efficacy in F only 0.27 0.12 0.04 0.27 0.12 0.04
1b - Stop after stage 1: efficacy in S only 0.01 0.04 0.10 0.01 0.04 0.10
1c - Stop after stage 1: efficacy in F and S 0.36 0.29 0.19 0.36 0.29 0.19
2 - Stop after stage 1: futility 0.04 0.10 0.17 0.08 0.19 0.29
3- Continue to stage 2: S only 0.08 0.22 0.38 0.07 0.18 0.29
4- Continue to stage 2: F only 0.14 0.11 0.06 0.17 0.14 0.06
5- Continue to stage 2: F and S 0.10 0.11 0.07 0.03 0.04 0.02
Table 3: Overall statistical power for IMpassion031 for the different scenarios and different
futility decision thresholds
dS = 0.12, dC = 0.1 dS = 0.15, dC = 0.12
Scen. 1 Scen. 2 Scen. 3 Scen. 1 Scen. 2 Scen. 3
Power F 0.80 0.54 0.28 0.79 0.52 0.27
Power S 0.49 0.57 0.61 0.45 0.51 0.55
Power (F or S) 0.88 0.76 0.67 0.86 0.71 0.61
Power (F and S) 0.41 0.35 0.22 0.38 0.32 0.20
Power (F or S) considers statistical significance achieved for either F
or S or both
15
Table 4: Conditional power (CP): Power conditional on activation of stage 2 for IMpassion031
for the different scenarios and different futility decision thresholds
dS = 0.12, dC = 0.1 dS = 0.15, dC = 0.12
Scen. 1 Scen. 2 Scen. 3 Scen. 1 Scen. 2 Scen. 3
CP F if only F tested in stage 2 0.67 0.46 0.27 0.74 0.57 0.40
CP S if only S tested in stage 2 0.77 0.76 0.74 0.84 0.83 0.82
CP (F or S) if F and S tested in stage 2 0.82 0.72 0.61 0.86 0.79 0.68
Table 5: Minimal detectable differences (MDDs) for the IMpassion031 trial, that is, ap-
proximate minimum absolute risk differences that would lead to a significant result in that
population after the respective stage.
Stage Subgroup S Full population F
Stage 1 0.25 [0.22] 0.17 [0.16]
Stage 2
- only S tested in stage 2 0.16
- only F tested in stage 2 0.13
- F and S included in stage 2 0.20 [0.17] 0.14 [0.12]
All MDDs assume a pCR probability of 0.48×0.95=0.456 in
the control arm accounting for 5% drop-outs. Numbers in
brackets are valid if the respective other population drives the
intersection test, that is, both populations statistically
significant but the respective other population has a lower
p-value.
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